Member Info for amones

Lauders, I saw a post during last week, either here or on another chat forum, suggesting possibility of a drop in sp when trading starts on SEHK. The reason given was the low price of IPO. I couldn’t understand how that was possible when majority of the new shares been allocated to the ‘cornerstone investors’ and also the fact the management had timed the SEHK listing to coincide with news of approval for Surufatinib and Savolitinib. Hence, out of curiosity asked opinions of other followers of HCM. Being a longtime holder, I too wish to see the sp reaching the previous heights it had achieved 2-3 years ago! SP has done very well during later part of last week.
(No recommendation intended)

‘Lucky’ 13.HK is set to start trading on Wednesday, 30/6. Where will the share price go on the opening day , Up or down? Anyone willing to predict?

Thanks Davey/Jatw.
In addition to opting for ticker “13.HK”, a lucky number, management has timed the IPO/HK listing to coincide with market encouraging news about Savo and Sulanda. Perfect timing! A similar news about FDA approval will be doing a lot good in the coming months, hopefully.

Has there been any news about the level of subscription to IPO? Also, are there any Asian websites similar to lse/advfn/stocktwits to follow 13.hk , once it starts trading? It will be interesting to see opinions of new followers/pi from Asia. Hopefully, the Asian shares related chat sites are not inundated with automated bots like the American site!

Thanks Davey. Another question about the global offer announced. Is (?was)t open for ex UK shareholders? Each new shares is one fifth of ADS, same value as AIM shares.

Expecting to see some information about Hong Kong IPO, I tried searching ‘Hutchmed’ on Yahoo Stocks app on my phone. In addition to the LSE and NYSE listed HCM shares, there are 3 or 4 Hutchmed (China) ‘symbols’ with Berlin and Frankfurt ‘listings’. Is anyone able to tell what these additional ‘listings’ are about?

Last couple of days of activity by these set of market makers. Once opened for trading on SEHK (and subsequently, ?on Shanghai) it will be a different ball game altogether, i think. Last Friday’s news of Surufatinib approval and impending Savolitinib news will be changing the outlook all together, imo.

Thanks Jatw and Tacly for explaining and posting the link quoting alibaba example. The “Full fungibility” of HCM stocks, listed at 3 different stock exchanges, would provide a mechanism for market makers to obtain shares from one exchange to meet the demands at other exchange/s.
(Note: only 13 million shares are offered in HK IPO. This is a smaller percentage compared to the global offer).

It is mentioned that the new IPO shares to be listed on SEHK will be ‘fungible’ with NYSE listed ADSs and AIM listed shares. What does it really mean?

Good timing!
Sulanda (Surufatinib) has got approval from Chinese authorities for treating Pancreatic Neuroendocrine tumors. (Previously, it was approved for treating non pancreatic NETs.)

Management have done a clever job of timing the IPO. Well done.

As per a post on advf., half of the global offer has already been ‘snaffled’ by existing institutional investors.

It is happening , after all that waiting!
Do we know the total value of the combined IPO (in $)?

One can only wish the timing of HKSE listing IPO to coincide with the much anticipated savo approval in China.

There is an ‘updated post’ on advf. about HKSE showing a green light for the ‘proposed ipo, as per people with knowledge’. Has anyone from the ‘pack of long-timers’ found any reliable information? Davey, you are the leader of the pack!

Thanks ttyn for searching this piece of good news.
At the outset, let us hope this news is genuine.
One can assume, being the first China based Pharmaceuticals to develop and market an oncological medicine and having an attractive pipeline, the initial placement of US $500 million worth of shares should be able to attract enough interest among local institutional investors.
Fingers crossed; a ray of light at the the end of the tunnel, at last.

Davey, I wasn’t able to watch the Wednesday’s session. You have mentioned about ‘potential partners’ for launching surufatinib in Europe. Any specific name/s got mentioned, as possible partners?

Good observation Jatw. Thursday’s Asian meet was followed by high volume of trading at NYSE (3x normal). ADSs’ price improved further on Friday as well, indicating ongoing interest.
Are investors/funds from Asia, specifically from HK/China, allowed to invest in stocks listed at NYSE? If so, we might see further action in the coming days.

Sorry, just noticed; it was Nov’ 2018.

Davey, thanks for the information. As you have correctly mentioned, the example of Innovent pharmaceuticals is ideal for comparison purposes. Do you Know which was the year Innovent got listed in Asia? 375% is pretty good. Obviously there could be other valid reasons for that kind of raise in valuation.
HCM had announced, in the previous years, that it was collaborating with Innovent for developing combination therapies using Innovent’s sintilimab with fruquintinib and surufatinib. Hopefully, we should be getting updates on Wednesday, about all such collaborations.

Davey, You have been following many other biotech companies trading on HK exchange. Few of those companies might have had listings on overseas ( US or European) exchanges and started trading at HK/STAR, at a later date. Is there an example of the ‘dilution factor’ affecting such companies’ sp? Most of the existing directors of HCM are holding significant numbers of shares. Would they be happy to allow dilution of their personal holdings ?

Oops! Sorry SS, I was, unduly, over enthusiastic!
However, CEO has been quite sensible in all his presentations so far.
Davey, I read a post by another investor here (?or advfn) mentioning CEO’s statement of ‘ exciting news’. Hopefully, something to feel better this time.